Founded in 1999, AngioGenex is a publicly held biopharmaceutical company that is engaged in the development of applications based on research into Id genes and proteins. It specializes in the discovery of Id-based products for the treatment and diagnosis of cancer and therapeutic care applications. The company additionally develops drugs for diabetes, retinopathy and endometriosis. It provides diagnostic products for oncological conditions and breast, melanoma and cervical cancers. The company specializes in a variety of procedures, such as coronary artery bypass grafting, balloon angioplasty and stent placement. AngioGenex has a partnership with BioCheck for the development and research of diagnostic and treatment products.